Analytical Framework for Examining the Value of Antibacterial Products. 3.2.9 Average Time to Generic Entry upon FDA Approval


We estimate the average time to generic entry upon obtaining FDA approval for the drug at 12 years based on a recent study by Grabowski et al. (2011).  For sensitivity analysis, we employ a triangular distribution with endpoints of 10 and 14 years, respectively.

View full report


"rpt_antibacterials.pdf" (pdf, 1.43Mb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®